Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies

Hack, J.; Crabb, Simon J.

doi:10.1016/j.clon.2022.02.015

Cited by 7 publications

(5 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 70 percent of OC patients diagnosed at an advanced stage develop metastases that result in a loss of surgery, due to the absence of early detection strategies and symptoms ( 2 ). For most OC patients, traditional chemotherapy has extremely high side effects and poor efficacy ( 3 ). Therefore, it is urgent to find effective diagnostic markers and therapeutic targets for ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance

Zhang

Zou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundOvarian cancer (OC) is one of the most common types of gynecologic tumor over the world. The Glutathione S-transferase Mu (GSTM) has five members, including GSTM1-5. These GSTMs is involved in cell metabolism and detoxification, but their role in OC remains unknown.MethodsData from multiple public databases associated with OC and GSTMs were collected. Expression, prognosis, function enrichment, immune infiltration, stemness index, and drug sensitivity analysis was utilized to identify the roles of GSTMs in OC progression. RT-qPCR analysis confirmed the effect of AICAR, AT-7519, PHA-793887 and PI-103 on the mRNA levels of GSTM3/4.ResultsGSTM1-5 were decreased in OC samples compared to normal ovary samples. GSTM1/5 were positively correlated with OC prognosis, but GSTM3 was negatively correlated with OC prognosis. Function enrichment analysis indicated GSTMs were involved in glutathione metabolism, drug metabolism, and drug resistance. Immune infiltration analysis indicated GSTM2/3/4 promoted immune escape in OC. GSTM5 was significantly correlated with OC stemness index. GSTM3/4 were remarkedly associated with OC chemoresistance, especially in AICAR, AT-7519, PHA-793887 and PI-103.ConclusionGSTM3 was negatively correlated with OC prognosis, and associated with OC chemoresistance and immune escape. This gene may serve as potential prognostic biomarkers and therapeutic target for OC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance

Zhang

Zou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Equally, it would seem remiss to discount any systemic therapy commenced for the purpose of controlling ABC, and which precludes concurrent systemic therapy, from this analysis. For ovarian cancer, the well-established concept of a platinum-free interval may help guide the utility of re-challenge therapy; although an interval of 6 months in that setting is a typical cut-off after which re-challenge may be beneficial, this is still not universally agreed, and differences are expected between tumour types [28]. Platinum-free interval did not influence inclusion in the present study.…”

Section: Discussionmentioning

confidence: 83%

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

Gray,

Letissier,

d’Abrigeon

et al. 2023

Cancers

View full text Add to dashboard Cite

Phase 3 trials have established standard first-line (1L) and 2L systemic therapy options for patients with advanced biliary cancer (ABC). However, a standard 3L treatment remains undefined. Clinical practice and outcomes for 3L systemic therapy in patients with ABC were therefore evaluated from three academic centres. Included patients were identified using institutional registries; demographics, staging, treatment history, and clinical outcomes were collected. Kaplan–Meier methods were used to assess progression-free survival (PFS) and overall survival (OS). Ninety-seven patients, treated between 2006 and 2022, were included; 61.9% had intrahepatic cholangiocarcinoma. At the time of analysis, there had been 91 deaths. Median PFS from initiating 3L palliative systemic therapy (mPFS3) was 3.1 months (95%CI 2.0–4.1), while mOS3 was 6.4 months (95%CI 5.5–7.3); mOS1 was 26.9 months (95%CI 23.6–30.2). Among patients with a therapy-targeted molecular aberration (10.3%; n = 10; all received in 3L), mOS3 was significantly improved versus all other included patients (12.5 vs. 5.9 months; p = 0.02). No differences in OS1 were demonstrated between anatomical subtypes. Fourth-line systemic therapy was received by 19.6% of patients (n = 19). This international multicentre analysis documents systemic therapy use in this select patient group, and provides a benchmark of outcomes for future trial design.

show abstract

“…Stratification factors used for randomisation included: hospital site, Ki-67 (<55% vs ≥ 55%), ECOG PS (0/1 vs 2), Presence of liver metastases (Yes/No), response to platinum-based chemotherapy (resistant: progression during platinum treatment or progression ≤6 months from platinum completion, sensitive: progression >6 months from platinum completion, or intolerant, acknowledging that there is no standard definition and a lack of quality evidence to support this description in PD-EP-NEC, and thus this wording has been adapted from accepted ovarian cancer practice). 24 Summary statistics and Kaplan–Meier survival curves for PFS and OS are presented. A logistic regression model was used to assess association between baseline NSE and PFS status at 6 months post randomisation (Baseline NSE was entered into the model as a continuous variable.…”

Section: Methodsmentioning

confidence: 99%

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

et al. 2023

View full text Add to dashboard Cite

Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies

Cited by 7 publications

References 102 publications

Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance

Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Contact Info

Product

Resources

About